Literature DB >> 7592033

New semisynthetic glycopeptides MDL 63,246 and MDL 63,042, and other amide derivatives of antibiotic A-40,926 active against highly glycopeptide-resistant VanA enterococci.

A Malabarba1, R Ciabatti, R Scotti, B P Goldstein, P Ferrari, M Kurz, B P Andreini, M Denaro.   

Abstract

A series of amide derivatives of natural glycopeptide A-40,926 (A), its 6B-methyl ester (MA) and 6B-decarboxy-6B-hydroxymethyl derivative (RA) were prepared with the aim of obtaining activity against glycopeptide-resistant enterococci. These compounds are structurally related to a class of amides of 34-de(acetylglucosaminyl)-34-deoxy teicoplanin which showed interesting activity against strains of Enterococcus faecalis and E. faecium highly resistant to both vancomycin and teicoplanin. Among them, RA-amides MDL 63,246 and MDL 63,042 were the most active derivatives against several Gram-positive bacteria, including VanB and VanC enterococci, and were moderately active (MIC range 0.5 approximately 64 micrograms/ml) against strains of Enterococcus for which vancomycin and teicoplanin MICs were > or = 128 micrograms/ml. The chemical rationale and the synthesis of these new series of glycopeptide derivatives are described. Preliminary in vitro data are reported and structure-activity relationships are discussed.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7592033     DOI: 10.7164/antibiotics.48.869

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  12 in total

Review 1.  Advancing cell wall inhibitors towards clinical applications.

Authors:  Sonia I Maffioli; João C S Cruz; Paolo Monciardini; Margherita Sosio; Stefano Donadio
Journal:  J Ind Microbiol Biotechnol       Date:  2015-10-29       Impact factor: 3.346

2.  Production of the glycopeptide antibiotic A40926 by Nonomuraea sp. ATCC 39727: influence of medium composition in batch fermentation.

Authors:  Nina Gunnarsson; Per Bruheim; Jens Nielsen
Journal:  J Ind Microbiol Biotechnol       Date:  2003-03-25       Impact factor: 3.346

3.  Semisynthetic glycopeptide antibiotics derived from LY264826 active against vancomycin-resistant enterococci.

Authors:  T I Nicas; D L Mullen; J E Flokowitsch; D A Preston; N J Snyder; M J Zweifel; S C Wilkie; M J Rodriguez; R C Thompson; R D Cooper
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

4.  A carrier protein strategy yields the structure of dalbavancin.

Authors:  Nicoleta J Economou; Virginie Nahoum; Stephen D Weeks; Kimberly C Grasty; Isaac J Zentner; Tracy M Townsend; Mohammad W Bhuiya; Simon Cocklin; Patrick J Loll
Journal:  J Am Chem Soc       Date:  2012-03-01       Impact factor: 15.419

5.  Characterization of a regiospecific epivancosaminyl transferase GtfA and enzymatic reconstitution of the antibiotic chloroeremomycin.

Authors:  Wei Lu; Markus Oberthür; Catherine Leimkuhler; Junhua Tao; Daniel Kahne; Christopher T Walsh
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-18       Impact factor: 11.205

Review 6.  Glycopeptide antibiotics: from conventional molecules to new derivatives.

Authors:  Françoise Van Bambeke; Yves Van Laethem; Patrice Courvalin; Paul M Tulkens
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 7.  Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review.

Authors:  Françoise Van Bambeke
Journal:  Drugs       Date:  2015-12       Impact factor: 9.546

Review 8.  A review on cell wall synthesis inhibitors with an emphasis on glycopeptide antibiotics.

Authors:  Paramita Sarkar; Venkateswarlu Yarlagadda; Chandradhish Ghosh; Jayanta Haldar
Journal:  Medchemcomm       Date:  2017-01-26       Impact factor: 3.597

9.  Anti-cooperative ligand binding and dimerisation in the glycopeptide antibiotic dalbavancin.

Authors:  Mu Cheng; Zyta M Ziora; Karl A Hansford; Mark A Blaskovich; Mark S Butler; Matthew A Cooper
Journal:  Org Biomol Chem       Date:  2014-04-28       Impact factor: 3.876

Review 10.  The modification of natural products for medical use.

Authors:  Zongru Guo
Journal:  Acta Pharm Sin B       Date:  2016-11-25       Impact factor: 11.413

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.